Membrane receptors for peptides in experimental and human pancreatic cancers

Matyas Fekete, A. Zalatnai, Ana Maria Comaru-Schally, Andrew Victor Schally

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased Bmax for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while Bmax for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist [D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

Original languageEnglish
Pages (from-to)521-528
Number of pages8
JournalPancreas.
Volume4
Issue number5
Publication statusPublished - 1989

Fingerprint

Peptide Receptors
Pancreatic Neoplasms
Gonadotropin-Releasing Hormone
Membranes
Cricetinae
Pancreas
Somatostatin
Epidermal Growth Factor
nitrosobis(2-oxopropyl)amine
Neoplasms
Epidermal Growth Factor Receptor
Capsules
Autopsy
Binding Sites

Keywords

  • Binding sites for luteinizing hormone-releasing hormone (LH-RH)
  • Epidermal growth factor
  • Hormonal manipulations
  • Pancreatic carcinoma
  • Somatostatin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Internal Medicine
  • Gastroenterology

Cite this

Fekete, M., Zalatnai, A., Comaru-Schally, A. M., & Schally, A. V. (1989). Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas., 4(5), 521-528.

Membrane receptors for peptides in experimental and human pancreatic cancers. / Fekete, Matyas; Zalatnai, A.; Comaru-Schally, Ana Maria; Schally, Andrew Victor.

In: Pancreas., Vol. 4, No. 5, 1989, p. 521-528.

Research output: Contribution to journalArticle

Fekete, M, Zalatnai, A, Comaru-Schally, AM & Schally, AV 1989, 'Membrane receptors for peptides in experimental and human pancreatic cancers', Pancreas., vol. 4, no. 5, pp. 521-528.
Fekete, Matyas ; Zalatnai, A. ; Comaru-Schally, Ana Maria ; Schally, Andrew Victor. / Membrane receptors for peptides in experimental and human pancreatic cancers. In: Pancreas. 1989 ; Vol. 4, No. 5. pp. 521-528.
@article{afbd0069adbc4da3b9d6c3215ce79ed1,
title = "Membrane receptors for peptides in experimental and human pancreatic cancers",
abstract = "Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased Bmax for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while Bmax for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist [D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.",
keywords = "Binding sites for luteinizing hormone-releasing hormone (LH-RH), Epidermal growth factor, Hormonal manipulations, Pancreatic carcinoma, Somatostatin",
author = "Matyas Fekete and A. Zalatnai and Comaru-Schally, {Ana Maria} and Schally, {Andrew Victor}",
year = "1989",
language = "English",
volume = "4",
pages = "521--528",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Membrane receptors for peptides in experimental and human pancreatic cancers

AU - Fekete, Matyas

AU - Zalatnai, A.

AU - Comaru-Schally, Ana Maria

AU - Schally, Andrew Victor

PY - 1989

Y1 - 1989

N2 - Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased Bmax for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while Bmax for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist [D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

AB - Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased Bmax for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while Bmax for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist [D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

KW - Binding sites for luteinizing hormone-releasing hormone (LH-RH)

KW - Epidermal growth factor

KW - Hormonal manipulations

KW - Pancreatic carcinoma

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0024437217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024437217&partnerID=8YFLogxK

M3 - Article

C2 - 2573055

AN - SCOPUS:0024437217

VL - 4

SP - 521

EP - 528

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -